Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.

Abstract

Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients who have inoperable or metastasized endocrine tumors. Symptomatic improvement may occur with all (111)In-, (90)Y-, or (177)Lu-labeled somatostatin analogs that have been used for peptide receptor radionuclide therapy. The results that were obtained with [(90)Y-DOTA degrees ,Tyr(3)]octreotide and [(177)Lu-DOTA degrees ,Tyr(3)]octreotate are encouraging in tumor regression. Also, if kidney-protective agents are used, the side effects of this therapy are few and mild. These data compare favorably with the limited number of alternative treatment approaches.

• Authors: Dik J Kwekkeboom, Jaap J M Teunissen, Boen L Kam, Roelf Valkema, Wouter W de Herder, Eric P Krenning
• Journal: Hematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 21 Issue 3 Pg. 561-73; x (Jun 2007) ISSN: 0889-8588 [Print] United States
• PMID: 17548040 (Publication Type: Journal Article, Review)

Chemical References

• Indium Radioisotopes
• Yttrium Radioisotopes
• Lutetium
• Octreotide

Topics

• Endocrine Gland Neoplasms (diagnosis, drug therapy, radiotherapy)
• Gastrointestinal Neoplasms (diagnosis, drug therapy, radiotherapy)
• Humans
• Indium Radioisotopes
• Lutetium
• Octreotide (analogs & derivatives, therapeutic use)
• Sensitivity and Specificity
• Tomography, X-Ray Computed (methods)
• Yttrium Radioisotopes